Changes of peripheral blood lymphocyte population in patients with head and neck squamous cell carcinoma undergoing concurrent chemotherapy

IF 2.5 4区医学 Q3 BIOCHEMICAL RESEARCH METHODS

SLAS Technology Pub Date : 2025-05-03 DOI:10.1016/j.slast.2025.100303

Guodong Man, Jianli Wang

{"title":"Changes of peripheral blood lymphocyte population in patients with head and neck squamous cell carcinoma undergoing concurrent chemotherapy","authors":"Guodong Man, Jianli Wang","doi":"10.1016/j.slast.2025.100303","DOIUrl":null,"url":null,"abstract":"<div><div>Although medical technology has improved the quality of life of HNSCC patients, their survival rate has not increased significantly, and their life and health continue to be threatened. With the help of modern medical technology, medical institutions can confirm the diagnosis of HNSCC patients in a timely manner, so as to take appropriate surgical treatment plans. However, surgery is difficult for patients with recurrent or metastatic HNSCC, and concurrent chemotherapy alone is not effective for HNSCC patients. Therefore, in this paper, the chemotherapy and immunotherapy of HNSCC patients were studied, and the following conclusions were drawn by detecting the peripheral blood lymphocytes of HNSCC patients. The NK cell (natural killer cell) index of healthy people was 6.64% higher than that of HNSCC patients. The CD4+/CD8+ ratio (CD4+ is inductive T cells and helper T cells, CD8+ is suppressor T cells and cytotoxic T cells) in HNSCC patients is in a downward trend during concurrent chemotherapy. Concurrent chemotherapy not only kills HNSCC cells, but also inhibits normal immune cells. The detection of peripheral blood lymphocytes of HNSCC patients has reference value for judging the immune function and curative effect of patients.</div></div>","PeriodicalId":54248,"journal":{"name":"SLAS Technology","volume":"32 ","pages":"Article 100303"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2472630325000615","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Although medical technology has improved the quality of life of HNSCC patients, their survival rate has not increased significantly, and their life and health continue to be threatened. With the help of modern medical technology, medical institutions can confirm the diagnosis of HNSCC patients in a timely manner, so as to take appropriate surgical treatment plans. However, surgery is difficult for patients with recurrent or metastatic HNSCC, and concurrent chemotherapy alone is not effective for HNSCC patients. Therefore, in this paper, the chemotherapy and immunotherapy of HNSCC patients were studied, and the following conclusions were drawn by detecting the peripheral blood lymphocytes of HNSCC patients. The NK cell (natural killer cell) index of healthy people was 6.64% higher than that of HNSCC patients. The CD4+/CD8+ ratio (CD4+ is inductive T cells and helper T cells, CD8+ is suppressor T cells and cytotoxic T cells) in HNSCC patients is in a downward trend during concurrent chemotherapy. Concurrent chemotherapy not only kills HNSCC cells, but also inhibits normal immune cells. The detection of peripheral blood lymphocytes of HNSCC patients has reference value for judging the immune function and curative effect of patients.

查看原文本刊更多论文

头颈部鳞状细胞癌同期化疗患者外周血淋巴细胞群的变化。

虽然医疗技术提高了HNSCC患者的生活质量，但其生存率并没有明显提高，其生命和健康继续受到威胁。在现代医疗技术的帮助下，医疗机构可以及时确认HNSCC患者的诊断，从而采取适当的手术治疗方案。然而，对于复发性或转移性HNSCC患者，手术治疗是困难的，同时单独化疗对HNSCC患者无效。因此，本文对HNSCC患者的化疗和免疫治疗进行了研究，通过检测HNSCC患者外周血淋巴细胞得出以下结论。健康人NK细胞（自然杀伤细胞）指数比HNSCC患者高6.64%。同期化疗期间，HNSCC患者CD4+/CD8+比值（CD4+为诱导性T细胞和辅助性T细胞，CD8+为抑制性T细胞和细胞毒性T细胞）呈下降趋势。同步化疗不仅可以杀死HNSCC细胞，还可以抑制正常的免疫细胞。HNSCC患者外周血淋巴细胞检测对判断患者免疫功能及疗效有参考价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SLAS Technology Computer Science-Computer Science Applications

CiteScore

6.30

自引率

7.40%

发文量

审稿时长

106 days

期刊介绍： SLAS Technology emphasizes scientific and technical advances that enable and improve life sciences research and development; drug-delivery; diagnostics; biomedical and molecular imaging; and personalized and precision medicine. This includes high-throughput and other laboratory automation technologies; micro/nanotechnologies; analytical, separation and quantitative techniques; synthetic chemistry and biology; informatics (data analysis, statistics, bio, genomic and chemoinformatics); and more.